Enovis CORP (ENOV) FY2025 10-K Annual Report
Enovis CORP (ENOV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Enovis CORP FY2025 10-K Analysis
Business Overview
- • Core business model: Orthopedic solutions via two segments—Prevention & Recovery (P&R) and Reconstructive (Recon) with global manufacturing and sales
- • New emphasis on Recon segment growth via $865.6M Lima acquisition in Jan 2024, adding digital innovation and customized hardware
Management Discussion & Analysis
- • Revenue $2.248B, up 5.1% YoY: P&R $1.137B (+$39M), Recon $1.111B (+$101.4M)
- • Operating loss margin worsened: P&R (32.9)% vs (29.3)%, Recon (67.5)% vs (45.0)% in 2024 due to goodwill impairments ($387.8M P&R, $662M Recon)
Risk Factors
- • Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports
- • Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing
Enovis CORP FY2025 Key Financial MetricsXBRL
Revenue
$2.2B
▲ +6.7% YoY
Net Income
-$1.2B
▼ -43.5% YoY
Gross Margin
59.8%
▲ +382bp YoY
Operating Margin
-50.0%
▼ -1320bp YoY
Net Margin
-52.7%
▼ -1352bp YoY
ROE
-79.5%
▼ -4729bp YoY
Total Assets
$3.8B
▼ -18.7% YoY
EPS (Diluted)
$-20.75
▼ -39.0% YoY
Operating Cash Flow
$217M
▲ +91.4% YoY
Source: XBRL data from Enovis CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Enovis CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.